Corticosteroid Therapy for Immune Thrombocytopenia

First-Line Corticosteroid Options

The American Society of Hematology recommends dexamethasone as a first-line corticosteroid option for immune thrombocytopenia (ITP), achieving platelet response in up to 80% of patients within 3 days 1, 2
Dexamethasone shows increased platelet count response at 7 days (RR 1.31; 95% CI 1.11-1.54) compared to prednisone, with a moderate strength of evidence 3
Higher remission rates (RR 2.96; 95% CI 1.03-8.45) are observed with dexamethasone, though with low certainty of evidence 3
Prednisone 1-2 mg/kg/day is effective at inducing response, with median time to platelet count >50,000/μL of 4 days versus 16 days in untreated patients, as recommended by the American College of Physicians 4, 2
High-dose methylprednisolone (HDMP) 30 mg/kg/day for 3 days followed by 20 mg/kg/day for 4 days is at least as effective as IVIg, with 60-100% achieving platelet response in 2-7 days, according to the National Institutes of Health 1, 2

Dexamethasone is preferred for rapid response needed within 7 days (emergency situations, active bleeding, pre-procedure), as recommended by the American Academy of Emergency Medicine 3
Prednisone/Methylprednisolone is preferred for longer-term therapy anticipated (>6 weeks), pediatric patients with ITP, patients with history of psychiatric disorders, or when better tolerability is needed for sustained treatment, according to the American Academy of Pediatrics and the American Psychiatric Association 3, 5

Dexamethasone has a significantly higher risk of neuropsychiatric adverse events (RR 4.55; 95% CI 2.45-8.46) and increased myopathy risk (RR 7.05; 95% CI 3.00-16.58), as reported by the FDA 2, 3
Prednisone/Methylprednisolone has a worse side-effect profile with high-dose methylprednisolone, and prolonged use causes serious adverse events, including weight gain, cataract, mood alterations, hypertension, infections, hyperglycemia, and osteoporosis, according to the National Institutes of Health 1, 2, 5

For life-threatening bleeding or organ-threatening situations, combine high-dose IV corticosteroids (methylprednisolone 30 mg/kg/day) PLUS IVIg (1 g/kg), as recommended by the American College of Emergency Physicians 4, 6, 7
Add platelet transfusions (2-3 fold larger than usual dose) to the combination therapy, according to the American Association of Blood Banks 1, 2

Corticosteroids should only be used to maintain hemostatic platelet count for as short a time as possible due to serious side effects with prolonged use, as recommended by the American Society of Hematology 1, 2
Patients requiring on-demand corticosteroids after first-line induction are considered non-responders and should be switched to second-line therapy, according to the National Institutes of Health 5
Initial response rates are 60-80%, but sustained responses only occur in 20-40% of patients, highlighting significant loss of long-term efficacy, as reported by the American Journal of Hematology 5